HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Nurix Therapeutics (NASDAQ: NRIX) and raised the price target from $34 to $36.